Global Antibody Contract Manufacturing Market Overview 2024, Forecast To 2033
8 Mar, 2024
The antibody contract manufacturing market, valued at $12.84 billion in 2023, will grow to $14.71 billion in 2024, with a CAGR of 14.6%. Increased R&D spending and biologics globalization contribute to this growth. Forecasts indicate growth to $25.27 billion by 2028, fueled by advancements in upstream technologies and sustainability initiatives, with trends like digitalization and contract integration.
Global Antibody Contract Manufacturing Market Key Driver
The antibody contract manufacturing market is poised for growth due to the rising number of clinical trials. With an increase in registered clinical trials globally, there is a higher demand for high-quality antibodies for research purposes.
Get A Free Sample Of The Global Antibody Contract Manufacturing Market ReportGlobal Antibody Contract Manufacturing Market Segments
The antibody contract manufacturing market covered in this report is segmented –
1) Product:Monoclonal Antibodies, Polyclonal Antibodies, Other Products
2) Source:Mammalian, Microbial
3) Scale Of Operation:Preclinical, Clinical, Commercial
4) End-User:Biopharmaceutical Companies, Research Laboratories, Other End Users
By Geography: The countries covered in the antibody contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the antibody contract manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Antibody Contract Manufacturing Industry Players
AbbVie Inc.; Thermo Fisher Scientific Inc.; Boehringer Ingelheim Biopharmaceuticals GmbH; Fujifilm Holdings Corporation; Eurofins Scientific SE; Lonza Group AG; Labcorp Drug Development; Catalent Inc.; Charles River Laboratories International Inc.; Merck KGaA; Samsung Biologics Co. Ltd.; Wuxi Biologics Cayman Inc; Pierre Fabre Group; Siegfried Holding AG; Recipharm AB; Emergent BioSolutions Inc.; Aenova Group; Cambrex Corporation; Aldevron LLC; Novasep Holding SAS; Synthon; KBI Biopharma Inc.; Nitto Avecia Pharma Services Inc.; Cytovance Biologics Inc.; AGC Biologics S.p.A.
Get The Full Global Antibody Contract Manufacturing Market Report
Antibody Contract Manufacturing Market Overview
Antibody contract manufacturing refers to outsourcing the production and manufacturing of antibodies to specialized contract manufacturing organizations (CMOs). These CMOs are equipped with the expertise, infrastructure, and resources necessary to manufacture antibodies on behalf of pharmaceutical and biotechnology companies.